TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04125368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Facility Interventions
Description: 1. Intensified counselling on dietary diversity and increased meal frequency during pregnancy.~2. Strengthened government distribution of IFA supplies with counseling about its importance, managing side effects, and reminder about subsequent supplies.~3. Weight-gain monitoring with messaging to mothers about healthy diet and adequate rest; excess weight gain as a danger sign.~4. Intensified counseling on importance, benefits, and how-tos of early initiation of breastfeeding and exclusive breastfeeding.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Interventions
Description: 1. Home visits to pregnant women by HEWs to discuss maternal nutrition (dietary diversity, adequate food intake, IFA supplementation, and weight gain), early breastfeeding practices, provide ANC and Pregnant Women Conference referrals, and engage husbands.~2. HEWs use A\&T intervention tools (e.g. posters and maternal nutrition follow-up card) at Pregnant Women Conferences/ Mother Support Groups to reinforce maternal nutrition messages, encourage ANC attendance, distribute IFA tablets, measure and track weight gain, promote early breastfeeding practices, and encourage husband participation.~3. HEWs and community volunteers (Women's Development Army (WDA), imams, etc.) deliver maternal nutrition messages and encourage ANC visits at kebele and community meetings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health System Interventions
Description: 1. Trainings on the maternal nutrition interventions for health center heads, nurse-midwives, HEWs, community volunteers (WDA, imams, etc.), woreda health officers, and other key actors.~2. Supportive supervision of maternal nutrition activities conducted by woreda nutrition officers, woreda health officers, TDA or A\&T.
Study: NCT02481310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or intraventricularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT or intraventricularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT02275260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebral Diffusion-Weighted Magnetic Resonance Imaging
Description: Patients undergo a cerebral Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transesophageal Echocardiography
Description: Patients undergo a Transesophageal Echocardiography prior to the ablation itself

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paperbased neurocognitive testing
Description: To assess the impact of PVI on the patient's neurocognitive status
Study: NCT03131414

Intervention type: OTHER
Intervention: Diet
Description: Dietary intake

Intervention type: OTHER
Intervention: Diet
Description: Dietary intake

Intervention type: OTHER
Intervention: Diet
Description: Dietary intake

Intervention type: OTHER
Intervention: Diet
Description: Dietary intake

Intervention type: OTHER
Intervention: Gastrointestinal microbiome
Description: Genomic sequencing of stool for gut bacteria

Intervention type: OTHER
Intervention: Gastrointestinal microbiome
Description: Genomic sequencing of stool for gut bacteria

Intervention type: OTHER
Intervention: Gastrointestinal microbiome
Description: Genomic sequencing of stool for gut bacteria

Intervention type: OTHER
Intervention: Gastrointestinal microbiome
Description: Genomic sequencing of stool for gut bacteria
Study: NCT01609699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with Contour I-Y system
Description: The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with Contour I-Y system
Description: The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with Contour I-Y system
Description: The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
Study: NCT05321238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High agency and immediate threat
Description: Participants were asked to make several decisions for the main character in the interactive digital narrative that related to drinking / turning down alcoholic drinks.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from acute alcohol poisoning after ingesting too much alcohol in a short period of time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High agency and distant threat
Description: Participants were asked to make several decisions for the main character in the interactive digital narrative that related to drinking / turning down alcoholic drinks.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from multiple organ failure after ingesting too much alcohol over a long period of time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low agency and immediate threat
Description: Participants were asked to read a narrative in which the main character turns down alcoholic drinks at a party. The participants can not influence the decisions of the main character and only consume the narrative passively.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from acute alcohol poisoning after ingesting too much alcohol in a short period of time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low agency and distant threat
Description: Participants were asked to read a narrative in which the main character turns down alcoholic drinks at a party. The participants can not influence the decisions of the main character and only consume the narrative passively.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from multiple organ failure after ingesting too much alcohol over a long period of time.
Study: NCT03675165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best Possible Self
Description: A writing exercise developed in 2001 by Laura King. The frequency of engagement with the exercise is down to the user's discretion though we recommend to them to write things down once every week for the duration of the study.
Study: NCT02481310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT or intraventricularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT02479568

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 500 mL (250 mL; 2 times/day) of placebo drink for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100% Florida OJ
Description: 500 mL (250 mL; 2 times/day) of 100% Florida OJ for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100% Florida OJ-enriched
Description: 500 mL (250 mL; 2 times/day) of 100% Florida OJ-enriched for 12 weeks
Study: NCT02063334

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: In total 25 pills will be taken by the subjects, each containing 80 micrograms of vitamin D3 or placebo. Of the 25 pills, 13 will be taken in the morning with breakfast and 12 with lunch.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04244890

Intervention type: DEVICE
Intervention: Uninterrupted CPAP for the first hours of life
Description: Directly at birth the infant will be supported with PPV with PEEP as needed, followed by nasal CPAP. Support will be provided with a single device for up to four hours.
Study: NCT01621698

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early paravertebral block
Description: In this group the local anaesthetic will be injected at the start of surgery soon after incision and normal saline at the end. These will be double blinded.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late Paravertebral block.
Description: In the late group local anaesthetic will be injected at close of surgery with normal saline at the start. This will be double blinded.
Study: NCT02577666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecologically Based Therapy
Description: 6 months of community reinforcement approach and case management, 3 months of rental assistance for housing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Housing Only
Description: receives 3 months of project supported rental assistance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: receives services as normally offered within the community

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: receives services as normally offered within the community

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: receives services as normally offered within the community
Study: NCT02126501

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gradual pressure wean
Description: NCPAP will be removed by gradually decreasing pressure over 24 hours once the weaning is decided
Study: NCT02885987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AmplifEYE
Description: AmplifEYE will be attached to the tip of the colonoscope prior to start of procedure.
Study: NCT00111670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPP-IV Inhibitor
Description: Escalating doses po bid or qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPP-IV Inhibitor
Description: Escalating doses po bid or qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPP-IV Inhibitor
Description: Escalating doses po bid or qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPP-IV Inhibitor
Description: Escalating doses po bid or qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po bid or qd
Study: NCT03263884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive trancranial magnetic stimulation (rTMS) group
Description: Repetitive trancranial magnetic stimulation is applied on the dorsolateral prefrontal cortex. The protocol consists on 20 minutes of 10Hz stimulation, 5 seconds on, 10 seconds off, at 110% RMT, for a total of 4000 pulses.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham group
Description: A sham coil is used to mimic the clicking sound of the trancranial magnetic coil and skin stimulation.
Study: NCT01459510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play Nicely Program
Description: Multi media educational intervention
Study: NCT02798510

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent Chemoradiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Study: NCT04789265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instrumented- assisted soft tissue mobilization (IASTM)
Description: IASTM is a new, non-invasive, conservative therapeutic approach. Instead of the therapist's hands and fingers in treatment, these devices are used to provide contact mobilization power. AYDM intervention, such as friction, rubbing massage treatments, requires the therapist to apply a significant amount of pressure. The main purpose of IASTM is to eliminate scar tissue and to restore the normal function of the tissue following soft tissue regeneration.
Study: NCT00993655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Carboplatin AUC 5 if measured GFR or AUC6 if calculated GFR intravenous or intraperitoneal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Carboplatin AUC 5 if measured GFR or AUC6 if calculated GFR intravenous or intraperitoneal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Cisplatin 75 mg/m2 intraperitoneal day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Paclitaxel 135 mg/m2 intravenous day 1 plus Paclitaxel 60 mg/m2 intraperitoneal or intravenously day 8. Cycles given Q 21 days x 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Paclitaxel 135 mg/m2 intravenous day 1 plus Paclitaxel 60 mg/m2 intraperitoneal or intravenously day 8. Cycles given Q 21 days x 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Paclitaxel 135 mg/m2 intravenous day 1 plus Paclitaxel 60 mg/m2 intraperitoneal or intravenously day 8. Cycles given Q 21 days x 3 cycles
Study: NCT02314624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation for Depression, Cognitive Behavior Therapy for Insomnia, Collaborative Assessment and Management of Suicidality
Description: Evidence-based interventions for treating depression and concurrent problems

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care-as-Usual Psychotherapy
Description: Usual care psychotherapy for depression and concurrent problems
Study: NCT05590780

Intervention type: OTHER
Intervention: Clinical Attachment level
Description: 1-year

Intervention type: OTHER
Intervention: Clinical Attachment level
Description: 1-year
Study: NCT00113880

Intervention type: BIOLOGICAL
Intervention: FluMist
Description: Nasal Sprayer dose of FluMist with annual follow up
Study: NCT00774306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenytoin
Description: Phenytoin is a anti-seizure medication. Participants will receive phenytoin (PHT) at 5 mg/kg/day in 2 divided doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valproate
Description: Valproate is an anti-seizure medication. Participants will receive valproate (VPA) at 15 mg/kg/day in 3 divided doses.
Study: NCT02096328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL7080
Description: Intravenous infusion
Study: NCT03489304

Intervention type: DRUG
Group type: OTHER
Intervention: Zaleplon
Description: non-benzodiazepine hypnotic agent
Study: NCT02073799

Intervention type: PROCEDURE
Intervention: Laser prostatectomy (Photoselective vaporization of the prostate or Holmium laser enucleation of the prostate)

Intervention type: PROCEDURE
Intervention: Laser prostatectomy (Photoselective vaporization of the prostate or Holmium laser enucleation of the prostate)
Study: NCT02425839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound exam by Supersonic Shear Imaging® technique
Description: Each of the two observers performs twice ultrasound examination and measures of the masseter thickness and its elastic modulus, at rest and maximal voluntary contraction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG examination by electromyograph Keypoint system
Description: Experimented neurologist performs EMG examination.
Study: NCT00950066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IRBESARTAN (SR47436)
Description: Oral administration of Irbesartan 150mg or 300mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IRBESARTAN (SR47436)
Description: Oral administration of Irbesartan 150mg or 300mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Oral administration of Amlodipine 5mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan / Amlodipine
Description: Oral administration of Irbesartan 150 mg / Amlodipine 5mg or Irbesartan 300mg / Amlodipine 5mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan / Amlodipine
Description: Oral administration of Irbesartan 150 mg / Amlodipine 5mg or Irbesartan 300mg / Amlodipine 5mg once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of a placebo once a day
Study: NCT04134156

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sleeve gastrectomy
Description: 5-port sleeve gastrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: one anastomosis gastric bypass
Description: 5-port one anastomosis gastric bypass
Study: NCT03436329

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vein ligation first
Description: During this procedure, patients undergo lobectomy with the pulmonary vein ligated first.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Artery ligation first
Description: During this procedure, patients undergo lobectomy with the pulmonary artery ligated first.
Study: NCT02642250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: The data will be recorded for physical examination including gender , age, height, weight, temperature, heart rate ,respiratory rate and blood pressure of the subject, number of stool per day, stool with or without mucus or mixed with blood along with abdominal cramps, dehydration, nausea, vomiting and related clinical information will be carefully recorded. Statistical tools and tabulated results will be used to identify the similarities and differences in safety, efficacy and tolerability of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entoban
Description: To evaluate the safety and efficacy of coded herbal formulation (Entoban) through randomized clinical study and compared with Metronidazole DS for treatment of gastrointestinal infections for improving the health of the community with due regard to the prevalence of disease and the feasibility of using alternative treatments.
Study: NCT03907280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162 (R)
Description: concentrate for i.v. solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162 (R)
Description: concentrate for i.v. solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162 (R)
Description: concentrate for i.v. solution
Study: NCT00616187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon beta treatment to add-on atorvastatin treatment
Description: IFN-β-1a 22 µg s.c. 3 times weekly or IFN-β-1b s.c. every other day (3 months baseline) and add on oral daily 80 mg atorvastatin (9 months add on treatment)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: untreated to atorvastatin treatment
Description: no treatment(3 months baseline)and oral daily 80 mg atorvastatin (9 months add on treatment)
Study: NCT03603080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of weight loss drug (Metformin or Topiramate)
Description: Patients in this arm will receive either Metformin (500 mg, twice per day) or Topiramate (50 mg, once per day) starting at 4 weeks after laparoscopic sleeve gastrectomy
Study: NCT02077348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin withdrawal
Description: Withdrawal of usual (evening) insulin, replaced by Insuman Rapid (10% of the amount of usual evening insulin) as a continuous IV- administration overnight until 8 o'clock on the study day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norditropin
Description: 0,4 mg of GH administered at 7.05 A.M. on the study day.
Study: NCT02935491

Intervention type: DEVICE
Intervention: Transcatheter Aortic Valve Implantation (TAVI)
Description: TAVI is a well-accepted method for aortic valve replacement without surgery. It is currently proposed to patients at high surgical risk or contraindicated to surgery. It consists of introducing a valve inserted inside a stent by the femoral artery in most cases.~Aortic calcifications will be determined by the analysis of the CT-scan performed systematically before the procedure. A semi-automated software (CreaTools) will be used
Study: NCT03817996

Intervention type: OTHER
Intervention: Fluid challenge
Description: 250ml of saline in Responders (those who increased \>10% their cardiac output after a passive leg raising maneuver).